New Delhi: Dangane da shawarar da Fresenius Medical Care ta gabatar, Kwamitin Kwararru na Musamman (SEC) na Ƙungiyar Kula da Magunguna ta Tsakiya (CDSCO) ya ba da shawarar kamfanin ya gabatar da dalilan amincewa tare da bayanan gwaji na mataki na uku na calcium chloride dihydrate da bayanan sa ido bayan tallatawa daga ƙasashen da aka amince da su don ƙarin nazari.
Kamfanin ya riga ya shigar da buƙatar ƙera da tallata maganin calcium chloride dihydrate mai yawan 100 mmol/L, wanda ake amfani da shi don "maganin maye gurbin calcium a cikin ci gaba da maganin maye gurbin koda (CRRT), ci gaba da ƙarancin inganci (kullum) dialysis (CLED) da kuma musayar plasma na warkewa (TPE) tare da citrate anticoagulation. Samfurin ya dace da manya da yara" kuma ya bayyana dalilan da suka sa aka cire shi daga gwaje-gwajen asibiti na mataki na III da mataki na IV.
Kwamitin ya lura cewa an amince da samfurin a ƙasashen Turai kamar Portugal, Birtaniya, Brazil, Switzerland, Faransa da Denmark.
Sinadarin calcium chloride dihydrate shine CaCl2 2H2O, wanda shine calcium chloride wanda ke ɗauke da ƙwayoyin ruwa guda biyu a kowace naúrar calcium chloride. Wani abu ne mai launin crystalline fari, wanda yake narkewa cikin ruwa kuma yana da hygroscopic, wato yana iya shan danshi daga iska.
Calcium chloride dihydrate wani sinadari ne da za a iya amfani da shi azaman tsarin narkewa don narke chitin lokacin da aka narkar da shi a cikin methanol. Yana taka muhimmiyar rawa wajen karya tsarin lu'ulu'u na chitin kuma yana da amfani iri-iri a fannin sinadarai.
A taron SEC Nephrology da aka gudanar a ranar 20 ga Mayu, 2025, kwamitin ya duba wani tsari na amincewa da kera da tallata maganin jiko na calcium chloride dihydrate mai nauyin 100 mmol/L don amfani a cikin "maganin maye gurbin calcium a cikin ci gaba da maganin maye gurbin koda (CRRT), ci gaba da ƙarancin inganci (kullum) dialysis (SLEDD), da kuma musayar plasma na warkewa (TPE) tare da citrate anticoagulation. An nuna samfurin ga manya da yara" kuma ya ba da hujjar keɓewa daga gwaje-gwajen asibiti na mataki na III da IV.
Bayan tattaunawa mai zurfi, kwamitin ya ba da shawarar cewa a gabatar da tushen amincewa, da kuma bayanan gwaji na asibiti na mataki na uku da kuma bayanan sa ido bayan tallatawa daga ƙasashen da suka amince da maganin, ga kwamitin don ƙarin nazari.
Karanta kuma: Ƙungiyar CDSCO Ta Amince Da Sabunta Lakabi Don Kamfanin Sanofi's Myozyme, Ta Nemi Sake Duba Dokokin Aiki
Dakta Divya Kolin ta kammala karatun digiri a fannin PharmD tare da kwarewa mai zurfi a fannin asibiti da asibiti da kuma ƙwarewar bincike da warkarwa mai kyau. Ta kuma yi aiki a matsayin mai harhada magunguna a fannin oncology a sashen oncology a Kwalejin Likitanci da Bincike ta Mysore. A halin yanzu tana ci gaba da aikinta a fannin bincike na asibiti da kuma kula da bayanai na asibiti. Tana aiki da Medical Dialogue tun daga watan Janairun 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Binciken ABYSS ya gano cewa dakatar da beta-blockers bayan bugun zuciya yana haifar da ƙaruwar hawan jini, bugun zuciya, da kuma abubuwan da ke haifar da cututtukan zuciya: ...